vs
Side-by-side financial comparison of Royalty Pharma plc (RPRX) and TRUPANION, INC. (TRUP). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $376.9M, roughly 1.7× TRUPANION, INC.). On growth, TRUPANION, INC. posted the faster year-over-year revenue change (11.7% vs 4.8%). Over the past eight quarters, TRUPANION, INC.'s revenue compounded faster (11.0% CAGR vs 4.6%).
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
TRUPANION, INC.TRUPEarnings & Financial Report
Trupanion, Inc. is a pet insurance provider headquartered in Seattle, Washington. Established in 1998, Trupanion operates across the United States, Canada, Australia, and Puerto Rico. The company offers coverage for pets and is self-underwritten by the American Pet Insurance Company (APIC).
RPRX vs TRUP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $622.0M | $376.9M |
| Net Profit | $214.2M | — |
| Gross Margin | — | 17.3% |
| Operating Margin | 62.4% | 1.9% |
| Net Margin | 34.4% | — |
| Revenue YoY | 4.8% | 11.7% |
| Net Profit YoY | 2.9% | — |
| EPS (diluted) | $0.49 | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $622.0M | $376.9M | ||
| Q3 25 | $609.3M | $366.9M | ||
| Q2 25 | $578.7M | $353.6M | ||
| Q1 25 | $568.2M | $342.0M | ||
| Q4 24 | $593.6M | $337.3M | ||
| Q3 24 | $564.7M | $327.5M | ||
| Q2 24 | $537.3M | $314.8M | ||
| Q1 24 | $568.0M | $306.1M |
| Q4 25 | $214.2M | — | ||
| Q3 25 | $288.2M | — | ||
| Q2 25 | $30.2M | — | ||
| Q1 25 | $238.3M | — | ||
| Q4 24 | $208.2M | — | ||
| Q3 24 | $544.0M | — | ||
| Q2 24 | $102.0M | — | ||
| Q1 24 | $4.8M | — |
| Q4 25 | — | 17.3% | ||
| Q3 25 | — | 16.4% | ||
| Q2 25 | — | 15.5% | ||
| Q1 25 | — | 14.9% | ||
| Q4 24 | — | 15.7% | ||
| Q3 24 | — | 15.1% | ||
| Q2 24 | — | 12.8% | ||
| Q1 24 | — | 11.8% |
| Q4 25 | 62.4% | 1.9% | ||
| Q3 25 | 70.1% | 1.6% | ||
| Q2 25 | 36.3% | 0.7% | ||
| Q1 25 | 94.0% | -0.4% | ||
| Q4 24 | 60.9% | 0.1% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | 50.2% | -1.7% | ||
| Q1 24 | -13.0% | -2.0% |
| Q4 25 | 34.4% | — | ||
| Q3 25 | 47.3% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 41.9% | — | ||
| Q4 24 | 35.1% | — | ||
| Q3 24 | 96.3% | — | ||
| Q2 24 | 19.0% | — | ||
| Q1 24 | 0.8% | — |
| Q4 25 | $0.49 | $0.13 | ||
| Q3 25 | $0.67 | $0.13 | ||
| Q2 25 | $0.07 | $0.22 | ||
| Q1 25 | $0.55 | $-0.03 | ||
| Q4 24 | $0.46 | $0.04 | ||
| Q3 24 | $1.21 | $0.03 | ||
| Q2 24 | $0.23 | $-0.14 | ||
| Q1 24 | $0.01 | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $618.7M | $370.7M |
| Total DebtLower is stronger | $9.0B | $101.8M |
| Stockholders' EquityBook value | $9.7B | $383.9M |
| Total Assets | $19.6B | $915.0M |
| Debt / EquityLower = less leverage | 0.92× | 0.27× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $618.7M | $370.7M | ||
| Q3 25 | $938.9M | $348.5M | ||
| Q2 25 | $631.9M | $319.6M | ||
| Q1 25 | $1.1B | $321.8M | ||
| Q4 24 | $929.0M | $307.4M | ||
| Q3 24 | $950.1M | $293.1M | ||
| Q2 24 | $1.8B | $277.2M | ||
| Q1 24 | $843.0M | $275.2M |
| Q4 25 | $9.0B | $101.8M | ||
| Q3 25 | $8.9B | — | ||
| Q2 25 | $8.0B | — | ||
| Q1 25 | $7.6B | — | ||
| Q4 24 | $7.6B | $127.5M | ||
| Q3 24 | $7.6B | — | ||
| Q2 24 | $7.6B | — | ||
| Q1 24 | $6.1B | — |
| Q4 25 | $9.7B | $383.9M | ||
| Q3 25 | $9.6B | $368.6M | ||
| Q2 25 | $9.5B | $355.5M | ||
| Q1 25 | $9.8B | $333.7M | ||
| Q4 24 | $10.3B | $323.3M | ||
| Q3 24 | $10.3B | $320.2M | ||
| Q2 24 | $9.8B | $305.8M | ||
| Q1 24 | $9.9B | $303.4M |
| Q4 25 | $19.6B | $915.0M | ||
| Q3 25 | $19.3B | $880.2M | ||
| Q2 25 | $18.3B | $847.8M | ||
| Q1 25 | $17.6B | $837.2M | ||
| Q4 24 | $18.2B | $806.9M | ||
| Q3 24 | $18.0B | $816.1M | ||
| Q2 24 | $17.7B | $795.9M | ||
| Q1 24 | $16.1B | $789.5M |
| Q4 25 | 0.92× | 0.27× | ||
| Q3 25 | 0.93× | — | ||
| Q2 25 | 0.84× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 0.74× | 0.39× | ||
| Q3 24 | 0.74× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.62× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $827.1M | $29.3M |
| Free Cash FlowOCF − Capex | — | $25.3M |
| FCF MarginFCF / Revenue | — | 6.7% |
| Capex IntensityCapex / Revenue | — | 1.0% |
| Cash ConversionOCF / Net Profit | 3.86× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $75.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $827.1M | $29.3M | ||
| Q3 25 | $702.6M | $29.2M | ||
| Q2 25 | $364.0M | $15.0M | ||
| Q1 25 | $596.1M | $16.0M | ||
| Q4 24 | $742.5M | $23.7M | ||
| Q3 24 | $703.6M | $15.3M | ||
| Q2 24 | $658.2M | $6.9M | ||
| Q1 24 | $664.6M | $2.4M |
| Q4 25 | — | $25.3M | ||
| Q3 25 | — | $23.9M | ||
| Q2 25 | — | $12.0M | ||
| Q1 25 | — | $14.0M | ||
| Q4 24 | — | $21.8M | ||
| Q3 24 | — | $13.4M | ||
| Q2 24 | — | $4.0M | ||
| Q1 24 | — | $-631.0K |
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 6.5% | ||
| Q2 25 | — | 3.4% | ||
| Q1 25 | — | 4.1% | ||
| Q4 24 | — | 6.5% | ||
| Q3 24 | — | 4.1% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | -0.2% |
| Q4 25 | — | 1.0% | ||
| Q3 25 | — | 1.4% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | 3.86× | — | ||
| Q3 25 | 2.44× | — | ||
| Q2 25 | 12.06× | — | ||
| Q1 25 | 2.50× | — | ||
| Q4 24 | 3.57× | — | ||
| Q3 24 | 1.29× | — | ||
| Q2 24 | 6.45× | — | ||
| Q1 24 | 139.10× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
TRUP
| Subscriptionbusiness | $261.4M | 69% |
| Other | $115.4M | 31% |
